25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GTG (Genetic Technologies Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Genetic Technologies Ltd together

I guess you are interested in Genetic Technologies Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Genetic Technologies Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – Genetic Technologies Ltd’s Price Targets

I'm going to help you getting a better view of Genetic Technologies Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Genetic Technologies Ltd

I send you an email if I find something interesting about Genetic Technologies Ltd.

1. Quick Overview

1.1. Quick analysis of Genetic Technologies Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Genetic Technologies Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$-0.24
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
A$-0.26
Return On Investment
-658.2%

For what price can you sell your share?

Current Price per Share
A$0.04
Expected price per share
A$0.039 - A$0.039
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Genetic Technologies Ltd (5 min.)




Live pricePrice per Share (EOD)
A$0.04
Intrinsic Value Per Share
A$-0.66 - A$-0.40
Total Value Per Share
A$-0.65 - A$-0.38

2.2. Growth of Genetic Technologies Ltd (5 min.)




Is Genetic Technologies Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$1.2m$7.3m-$6.1m-509.8%

How much money is Genetic Technologies Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$7.8m-$7.7m-$174.9k-2.2%
Net Profit Margin-156.8%-113.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Genetic Technologies Ltd (5 min.)




2.4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#111 / 127

Most Revenue
#96 / 127

Most Profit
#88 / 127

Most Efficient
#107 / 127
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Genetic Technologies Ltd?

Welcome investor! Genetic Technologies Ltd's management wants to use your money to grow the business. In return you get a share of Genetic Technologies Ltd.

First you should know what it really means to hold a share of Genetic Technologies Ltd. And how you can make/lose money.

Speculation

The Price per Share of Genetic Technologies Ltd is A$0.039. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genetic Technologies Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genetic Technologies Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genetic Technologies Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.05-139.2%-0.05-139.2%-0.05-136.1%-0.05-119.3%-0.04-102.1%-0.04-94.5%
Usd Book Value Change Per Share-0.04-108.1%-0.04-108.1%-0.02-61.0%-0.03-76.1%0.000.1%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.04-108.1%-0.04-108.1%-0.02-61.0%-0.03-76.1%0.000.1%0.000.0%
Usd Price Per Share0.05-0.05-0.00-0.02-0.01-0.01-
Price to Earnings Ratio-0.91--0.91--0.03--0.33--0.26--0.26-
Price-to-Total Gains Ratio-1.17--1.17--0.07--0.44--0.22--0.26-
Price to Book Ratio5.96-5.96-0.03-2.01-1.23-0.75-
Price-to-Total Gains Ratio-1.17--1.17--0.07--0.44--0.22--0.26-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0256152
Number of shares39039
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.00
Usd Total Gains Per Share-0.040.00
Gains per Quarter (39039 shares)-1,645.502.09
Gains per Year (39039 shares)-6,582.028.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-6582-659208-2
20-13164-131740176
30-19746-1975602514
40-26328-2633803322
50-32910-3292004230
60-39492-3950205038
70-46074-4608405846
80-52656-5266606754
90-59238-5924807562
100-65820-6583008470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.024.00.04.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.07.00.030.0%10.015.00.040.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.025.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.07.00.030.0%10.015.00.040.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Genetic Technologies Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.064-0.0640%-0.036-44%-0.045-30%0.000-78907%0.000-3222531%
Book Value Per Share--0.0130.0130%0.077-84%0.067-81%0.089-86%0.078-84%
Current Ratio--0.8810.8810%3.170-72%2.637-67%6.921-87%6.919-87%
Debt To Asset Ratio--0.7040.7040%0.249+183%0.388+82%0.266+165%0.234+201%
Debt To Equity Ratio--2.3802.3800%0.331+619%0.992+140%0.632+276%0.467+410%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--7570776.4007570776.4000%4538518.480+67%6635414.619+14%10781763.050-30%10464008.069-28%
Eps---0.083-0.0830%-0.081-2%-0.071-14%-0.061-27%-0.056-32%
Ev To Ebitda Ratio---0.662-0.6620%-0.405-39%-0.717+8%-1.458+120%-1.387+109%
Ev To Sales Ratio--0.9880.9880%0.439+125%0.858+15%304.582-100%165.907-99%
Free Cash Flow Per Share---0.067-0.0670%-0.067+0%-0.058-13%-0.052-22%-0.051-23%
Free Cash Flow To Equity Per Share---0.047-0.0470%-0.026-45%-0.038-19%0.004-1300%-0.001-99%
Gross Profit Margin--1.2171.2170%1.251-3%1.244-2%1.199+2%1.249-3%
Intrinsic Value_10Y_max---0.397----------
Intrinsic Value_10Y_min---0.660----------
Intrinsic Value_1Y_max---0.049----------
Intrinsic Value_1Y_min---0.061----------
Intrinsic Value_3Y_max---0.140----------
Intrinsic Value_3Y_min---0.188----------
Intrinsic Value_5Y_max---0.223----------
Intrinsic Value_5Y_min---0.321----------
Market Cap5671262.688-92%10906274.40010906274.4000%363542.480+2900%3902022.619+180%2733839.450+299%2384838.669+357%
Net Profit Margin---1.568-1.5680%-1.136-28%-1.251-20%-136.153+8584%-100.903+6336%
Operating Margin---1.561-1.5610%-1.148-26%-1.285-18%-136.643+8653%-97.977+6176%
Operating Ratio--2.5932.5930%2.169+20%1.756+48%140.687-98%101.017-97%
Pb Ratio3.098-92%5.9585.9580%0.033+18195%2.006+197%1.225+386%0.747+697%
Pe Ratio-0.472+48%-0.908-0.9080%-0.031-97%-0.333-63%-0.259-71%-0.261-71%
Price Per Share0.039-92%0.0750.0750%0.003+2900%0.027+180%0.019+299%0.016+357%
Price To Free Cash Flow Ratio-0.584+48%-1.123-1.1230%-0.037-97%-0.412-63%-0.308-73%-0.284-75%
Price To Total Gains Ratio-0.608+48%-1.169-1.1690%-0.069-94%-0.441-62%-0.220-81%-0.258-78%
Quick Ratio--0.7550.7550%2.439-69%2.303-67%6.550-88%6.527-88%
Return On Assets---1.942-1.9420%-0.791-59%-1.025-47%-0.755-61%-0.851-56%
Return On Equity---6.565-6.5650%-1.053-84%-2.684-59%-1.763-73%-1.580-76%
Total Gains Per Share---0.064-0.0640%-0.036-44%-0.045-30%0.000-78907%0.000-3222531%
Usd Book Value--1202216.5721202216.5720%7331579.917-84%6441907.974-81%8531793.117-86%7412268.388-84%
Usd Book Value Change Per Share---0.042-0.0420%-0.024-44%-0.030-30%0.000-78907%0.000-3222531%
Usd Book Value Per Share--0.0080.0080%0.050-84%0.044-81%0.059-86%0.051-84%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--4972485.9404972485.9400%2980898.938+67%4358140.322+14%7081461.971-30%6872760.500-28%
Usd Eps---0.054-0.0540%-0.053-2%-0.047-14%-0.040-27%-0.037-32%
Usd Free Cash Flow---6378851.452-6378851.4520%-6397656.950+0%-5519071.134-13%-4978155.043-22%-4901193.058-23%
Usd Free Cash Flow Per Share---0.044-0.0440%-0.044+0%-0.038-13%-0.034-22%-0.034-23%
Usd Free Cash Flow To Equity Per Share---0.031-0.0310%-0.017-45%-0.025-19%0.003-1300%0.000-99%
Usd Market Cap3724885.333-92%7163241.0267163241.0260%238774.701+2900%2562848.456+180%1795585.750+299%1566362.038+357%
Usd Price Per Share0.026-92%0.0490.0490%0.002+2900%0.018+180%0.012+299%0.011+357%
Usd Profit---7892909.439-7892909.4390%-7718006.226-2%-6764851.717-14%-5789782.507-27%-5388755.533-32%
Usd Revenue--5034230.1315034230.1310%6796504.661-26%5431189.980-7%3275845.697+54%1872381.270+169%
Usd Total Gains Per Share---0.042-0.0420%-0.024-44%-0.030-30%0.000-78907%0.000-3222531%
 EOD+3 -5MRQTTM+0 -0YOY+11 -273Y+9 -295Y+11 -2710Y+10 -28

3.3 Fundamental Score

Let's check the fundamental score of Genetic Technologies Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.472
Price to Book Ratio (EOD)Between0-13.098
Net Profit Margin (MRQ)Greater than0-1.568
Operating Margin (MRQ)Greater than0-1.561
Quick Ratio (MRQ)Greater than10.755
Current Ratio (MRQ)Greater than10.881
Debt to Asset Ratio (MRQ)Less than10.704
Debt to Equity Ratio (MRQ)Less than12.380
Return on Equity (MRQ)Greater than0.15-6.565
Return on Assets (MRQ)Greater than0.05-1.942
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Genetic Technologies Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.039
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Genetic Technologies Ltd

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Maroochydore, Australia.

Fundamental data was last updated by Penke on 2025-06-29 17:30:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Genetic Technologies Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Genetic Technologies Ltd to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -156.8% means that $-1.57 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genetic Technologies Ltd:

  • The MRQ is -156.8%. The company is making a huge loss. -2
  • The TTM is -156.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-156.8%TTM-156.8%0.0%
TTM-156.8%YOY-113.6%-43.2%
TTM-156.8%5Y-13,615.3%+13,458.5%
5Y-13,615.3%10Y-10,090.3%-3,524.9%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-156.8%-5.0%-151.8%
TTM-156.8%-5.8%-151.0%
YOY-113.6%-9.0%-104.6%
3Y-125.1%-8.5%-116.6%
5Y-13,615.3%-4.9%-13,610.4%
10Y-10,090.3%-1.8%-10,088.5%
4.3.1.2. Return on Assets

Shows how efficient Genetic Technologies Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genetic Technologies Ltd to the Diagnostics & Research industry mean.
  • -194.2% Return on Assets means that Genetic Technologies Ltd generated $-1.94 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genetic Technologies Ltd:

  • The MRQ is -194.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -194.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-194.2%TTM-194.2%0.0%
TTM-194.2%YOY-79.1%-115.2%
TTM-194.2%5Y-75.5%-118.8%
5Y-75.5%10Y-85.1%+9.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-194.2%-0.7%-193.5%
TTM-194.2%-0.8%-193.4%
YOY-79.1%-1.3%-77.8%
3Y-102.5%-1.4%-101.1%
5Y-75.5%--75.5%
10Y-85.1%0.1%-85.2%
4.3.1.3. Return on Equity

Shows how efficient Genetic Technologies Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genetic Technologies Ltd to the Diagnostics & Research industry mean.
  • -656.5% Return on Equity means Genetic Technologies Ltd generated $-6.57 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genetic Technologies Ltd:

  • The MRQ is -656.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -656.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-656.5%TTM-656.5%0.0%
TTM-656.5%YOY-105.3%-551.3%
TTM-656.5%5Y-176.3%-480.2%
5Y-176.3%10Y-158.0%-18.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-656.5%-0.8%-655.7%
TTM-656.5%-0.8%-655.7%
YOY-105.3%-2.0%-103.3%
3Y-268.4%-1.7%-266.7%
5Y-176.3%-1.0%-175.3%
10Y-158.0%-1.4%-156.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Genetic Technologies Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Genetic Technologies Ltd is operating .

  • Measures how much profit Genetic Technologies Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genetic Technologies Ltd to the Diagnostics & Research industry mean.
  • An Operating Margin of -156.1% means the company generated $-1.56  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genetic Technologies Ltd:

  • The MRQ is -156.1%. The company is operating very inefficient. -2
  • The TTM is -156.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-156.1%TTM-156.1%0.0%
TTM-156.1%YOY-114.8%-41.3%
TTM-156.1%5Y-13,664.3%+13,508.1%
5Y-13,664.3%10Y-9,797.7%-3,866.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-156.1%-2.1%-154.0%
TTM-156.1%-11.2%-144.9%
YOY-114.8%-8.5%-106.3%
3Y-128.5%-1.7%-126.8%
5Y-13,664.3%3.2%-13,667.5%
10Y-9,797.7%4.0%-9,801.7%
4.3.2.2. Operating Ratio

Measures how efficient Genetic Technologies Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 2.59 means that the operating costs are $2.59 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genetic Technologies Ltd:

  • The MRQ is 2.593. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.593. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.593TTM2.5930.000
TTM2.593YOY2.169+0.424
TTM2.5935Y140.687-138.094
5Y140.68710Y101.017+39.670
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5931.344+1.249
TTM2.5931.302+1.291
YOY2.1691.292+0.877
3Y1.7561.276+0.480
5Y140.6871.265+139.422
10Y101.0171.192+99.825
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Genetic Technologies Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Genetic Technologies Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 0.88 means the company has $0.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genetic Technologies Ltd:

  • The MRQ is 0.881. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.881. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.881TTM0.8810.000
TTM0.881YOY3.170-2.289
TTM0.8815Y6.921-6.040
5Y6.92110Y6.919+0.001
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8812.037-1.156
TTM0.8812.055-1.174
YOY3.1702.374+0.796
3Y2.6372.414+0.223
5Y6.9212.552+4.369
10Y6.9192.974+3.945
4.4.3.2. Quick Ratio

Measures if Genetic Technologies Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genetic Technologies Ltd to the Diagnostics & Research industry mean.
  • A Quick Ratio of 0.75 means the company can pay off $0.75 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genetic Technologies Ltd:

  • The MRQ is 0.755. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.755. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.755TTM0.7550.000
TTM0.755YOY2.439-1.684
TTM0.7555Y6.550-5.795
5Y6.55010Y6.527+0.023
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7551.089-0.334
TTM0.7551.186-0.431
YOY2.4391.354+1.085
3Y2.3031.538+0.765
5Y6.5501.803+4.747
10Y6.5272.090+4.437
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Genetic Technologies Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Genetic Technologies Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genetic Technologies Ltd to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.70 means that Genetic Technologies Ltd assets are financed with 70.4% credit (debt) and the remaining percentage (100% - 70.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genetic Technologies Ltd:

  • The MRQ is 0.704. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.704. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.704TTM0.7040.000
TTM0.704YOY0.249+0.456
TTM0.7045Y0.266+0.438
5Y0.26610Y0.234+0.032
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7040.385+0.319
TTM0.7040.432+0.272
YOY0.2490.390-0.141
3Y0.3880.389-0.001
5Y0.2660.410-0.144
10Y0.2340.454-0.220
4.5.4.2. Debt to Equity Ratio

Measures if Genetic Technologies Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genetic Technologies Ltd to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 238.0% means that company has $2.38 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genetic Technologies Ltd:

  • The MRQ is 2.380. The company is just not able to pay all its debts with equity.
  • The TTM is 2.380. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.380TTM2.3800.000
TTM2.380YOY0.331+2.049
TTM2.3805Y0.632+1.748
5Y0.63210Y0.467+0.165
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3800.604+1.776
TTM2.3800.612+1.768
YOY0.3310.589-0.258
3Y0.9920.702+0.290
5Y0.6320.674-0.042
10Y0.4670.657-0.190
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Genetic Technologies Ltd generates.

  • Above 15 is considered overpriced but always compare Genetic Technologies Ltd to the Diagnostics & Research industry mean.
  • A PE ratio of -0.91 means the investor is paying $-0.91 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genetic Technologies Ltd:

  • The EOD is -0.472. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.908. Based on the earnings, the company is expensive. -2
  • The TTM is -0.908. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.472MRQ-0.908+0.436
MRQ-0.908TTM-0.9080.000
TTM-0.908YOY-0.031-0.877
TTM-0.9085Y-0.259-0.649
5Y-0.25910Y-0.261+0.002
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.472-0.557+0.085
MRQ-0.908-0.732-0.176
TTM-0.908-0.516-0.392
YOY-0.031-0.153+0.122
3Y-0.333-0.088-0.245
5Y-0.2595.675-5.934
10Y-0.2617.829-8.090
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genetic Technologies Ltd:

  • The EOD is -0.584. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.123. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.123. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.584MRQ-1.123+0.539
MRQ-1.123TTM-1.1230.000
TTM-1.123YOY-0.037-1.086
TTM-1.1235Y-0.308-0.815
5Y-0.30810Y-0.284-0.024
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.584-1.028+0.444
MRQ-1.123-1.081-0.042
TTM-1.123-0.778-0.345
YOY-0.037-1.057+1.020
3Y-0.412-0.521+0.109
5Y-0.308-0.680+0.372
10Y-0.284-0.697+0.413
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Genetic Technologies Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 5.96 means the investor is paying $5.96 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Genetic Technologies Ltd:

  • The EOD is 3.098. Based on the equity, the company is fair priced.
  • The MRQ is 5.958. Based on the equity, the company is overpriced. -1
  • The TTM is 5.958. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.098MRQ5.958-2.860
MRQ5.958TTM5.9580.000
TTM5.958YOY0.033+5.926
TTM5.9585Y1.225+4.733
5Y1.22510Y0.747+0.478
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD3.0982.054+1.044
MRQ5.9582.072+3.886
TTM5.9582.188+3.770
YOY0.0332.305-2.272
3Y2.0062.476-0.470
5Y1.2253.467-2.242
10Y0.7474.356-3.609
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Genetic Technologies Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Long-term Assets Other  -440-9,100-9,5403,455-6,0851,848-4,2374,31882
Net Working Capital  13,7957,03620,831-9,92610,905-3,7197,186-7,686-500



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets6,187
Total Liabilities4,356
Total Stockholder Equity1,830
 As reported
Total Liabilities 4,356
Total Stockholder Equity+ 1,830
Total Assets = 6,187

Assets

Total Assets6,187
Total Current Assets3,695
Long-term Assets2,491
Total Current Assets
Cash And Cash Equivalents 1,021
Short-term Investments 19
Net Receivables 2,127
Inventory 206
Other Current Assets 342
Total Current Assets  (as reported)3,695
Total Current Assets  (calculated)3,714
+/- 19
Long-term Assets
Property Plant Equipment 264
Goodwill 1,785
Intangible Assets 360
Long-term Assets Other 82
Long-term Assets  (as reported)2,491
Long-term Assets  (calculated)2,491
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,195
Long-term Liabilities161
Total Stockholder Equity1,830
Total Current Liabilities
Short-term Debt 852
Short Long Term Debt 644
Accounts payable 1,458
Other Current Liabilities 1,143
Total Current Liabilities  (as reported)4,195
Total Current Liabilities  (calculated)4,097
+/- 98
Long-term Liabilities
Capital Lease Obligations 232
Long-term Liabilities  (as reported)161
Long-term Liabilities  (calculated)232
+/- 71
Total Stockholder Equity
Common Stock163,818
Retained Earnings -166,376
Accumulated Other Comprehensive Income 4,389
Total Stockholder Equity (as reported)1,830
Total Stockholder Equity (calculated)1,830
+/-0
Other
Capital Stock163,818
Cash and Short Term Investments 1,021
Common Stock Shares Outstanding 138,367
Current Deferred Revenue742
Liabilities and Stockholders Equity 6,187
Net Debt -145
Net Invested Capital 2,474
Net Working Capital -500
Property Plant and Equipment Gross 1,530
Short Long Term Debt Total 875



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-30
> Total Assets 
8,847
39,686
33,001
30,245
22,389
29,264
22,442
20,952
24,146
22,276
8,280
8,922
16,442
8,320
6,729
20,720
13,290
12,108
6,166
3,265
15,633
22,972
20,802
14,856
6,187
6,18714,85620,80222,97215,6333,2656,16612,10813,29020,7206,7298,32016,4428,9228,28022,27624,14620,95222,44229,26422,38930,24533,00139,6868,847
   > Total Current Assets 
5,402
3,382
8,245
7,373
12,964
19,675
13,092
13,651
15,928
12,519
4,502
6,255
9,950
2,657
4,361
19,566
12,131
11,632
5,991
3,196
15,193
22,236
14,717
10,498
3,695
3,69510,49814,71722,23615,1933,1965,99111,63212,13119,5664,3612,6579,9506,2554,50212,51915,92813,65113,09219,67512,9647,3738,2453,3825,402
       Cash And Cash Equivalents 
1,229
646
7,160
5,829
11,299
17,658
11,102
12,460
12,949
9,698
3,306
5,105
8,900
1,721
2,831
18,341
11,180
10,988
5,487
2,132
14,214
20,902
11,731
7,851
1,021
1,0217,85111,73120,90214,2142,1325,48710,98811,18018,3412,8311,7218,9005,1053,3069,69812,94912,46011,10217,65811,2995,8297,1606461,229
       Short-term Investments 
0
0
70
262
38
88
0
77
519
0
72
3
17
209
3
4
4
3
4
53
2
2
13
17
19
19171322534344320917372051977088382627000
       Net Receivables 
89
191
233
1,237
1,627
572
1,401
647
1,597
1,824
755
674
438
329
895
525
393
201
11
17
39
1,074
2,421
192
2,127
2,1271922,4211,0743917112013935258953294386747551,8241,5976471,4015721,6271,23723319189
       Inventory 
4,083
2,458
782
258
0
0
588
544
859
554
298
474
317
214
213
317
167
77
59
32
91
77
398
326
206
2063263987791325977167317213214317474298554859544588002587822,4584,083
   > Long-term Assets 
3,445
36,304
24,756
22,872
9,425
9,589
9,350
7,301
8,218
9,757
3,777
2,667
6,492
5,662
1,573
1,154
1,159
477
175
69
440
736
6,085
4,237
2,491
2,4914,2376,085736440691754771,1591,1541,5735,6626,4922,6673,7779,7578,2187,3019,3509,5899,42522,87224,75636,3043,445
       Property Plant Equipment 
334
801
492
1,490
1,841
2,604
2,267
1,946
1,707
3,730
1,978
948
643
423
394
418
550
477
175
69
440
638
953
599
264
264599953638440691754775504183944236439481,9783,7301,7071,9462,2672,6041,8411,490492801334
       Goodwill 
0
24,509
405
453
413
455
346
346
316
1,582
318
315
315
315
315
0
0
0
0
0
0
4,507
4,507
3,117
1,785
1,7853,1174,5074,5070000003153153153153181,58231634634645541345340524,5090
       Intangible Assets 
0
27,364
23,985
20,179
6,862
6,246
5,148
3,349
5,987
5,712
1,482
1,404
1,119
991
864
736
608
0
0
0
0
5,132
625
520
360
3605206255,13200006087368649911,1191,4041,4825,7125,9873,3495,1486,2466,86220,17923,98527,3640
       Long-term Assets Other 
3,112
8,140
279
750
722
740
1,589
1,658
208
-1,102
0
0
0
-5,662
-1,573
-1,154
-1,159
-477
-2,500
-69
-440
-9,540
-6,085
-4,237
82
82-4,237-6,085-9,540-440-69-2,500-477-1,159-1,154-1,573-5,662000-1,1022081,6581,5897407227502798,1403,112
> Total Liabilities 
1,270
1,618
1,865
2,968
5,321
6,510
4,176
4,051
3,317
4,790
2,562
2,108
2,039
2,561
4,902
1,760
1,406
1,529
1,454
1,494
1,640
1,439
4,371
3,694
4,356
4,3563,6944,3711,4391,6401,4941,4541,5291,4061,7604,9022,5612,0392,1082,5624,7903,3174,0514,1766,5105,3212,9681,8651,6181,270
   > Total Current Liabilities 
1,270
1,618
1,865
2,968
4,624
4,903
2,947
3,252
3,054
4,683
2,479
2,026
1,931
2,465
2,318
1,735
1,332
1,465
1,451
1,493
1,398
1,405
3,812
3,312
4,195
4,1953,3123,8121,4051,3981,4931,4511,4651,3321,7352,3182,4651,9312,0262,4794,6833,0543,2522,9474,9034,6242,9681,8651,6181,270
       Short-term Debt 
0
120
0
0
0
435
491
477
111
373
383
68
18
209
153
25
4
3
4
241
241
180
264
304
852
8523042641802412414342515320918683833731114774914350001200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,502
25
0
0
0
0
0
0
0
0
644
64400000000252,50200000000000000
       Accounts payable 
385
446
717
1,379
2,004
3,002
1,411
1,177
1,786
2,159
1,196
653
333
622
900
517
392
398
536
590
350
270
1,154
838
1,458
1,4588381,1542703505905363983925179006223336531,1962,1591,7861,1771,4113,0022,0041,379717446385
       Other Current Liabilities 
1,270
1,498
1,865
252
1,958
949
1,012
1,273
684
559
706
1,141
1,314
1,522
1,418
1,116
940
1,067
915
903
807
955
1,580
1,321
1,143
1,1431,3211,5809558079039151,0679401,1161,4181,5221,3141,1417065596841,2731,0129491,9582521,8651,4981,270
   > Long-term Liabilities 
0
0
0
697
696
1,607
1,229
798
263
107
83
83
109
96
2,502
25
74
64
2,503
1
52
33
559
382
161
161382559335212,5036474252,5029610983831072637981,2291,607696697000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
241
24
388
229
0
02293882424100000000000000000000
       Other Liabilities 
0
0
0
0
0
0
37
50
75
86
83
83
109
96
81
25
74
64
3
1
979
9
171
152
0
01521719979136474258196109838386755037000000
> Total Stockholder Equity
7,577
38,068
31,136
27,277
16,951
22,590
18,091
16,756
20,688
17,294
5,533
6,612
14,248
5,638
1,828
18,959
11,883
10,579
4,712
1,771
13,993
21,533
16,431
11,163
1,830
1,83011,16316,43121,53313,9931,7714,71210,57911,88318,9591,8285,63814,2486,6125,53317,29420,68816,75618,09122,59016,95127,27731,13638,0687,577
   Common Stock
20,212
53,957
39,351
39,684
24,732
36,164
37,993
70,244
70,244
88,329
72,378
72,378
83,280
83,736
90,080
115,247
115,273
122,383
122,373
125,499
140,111
153,575
155,139
161,343
163,818
163,818161,343155,139153,575140,111125,499122,373122,383115,273115,24790,08083,73683,28072,37872,37888,32970,24470,24437,99336,16424,73239,68439,35153,95720,212
   Retained Earnings -166,376-156,716-150,206-143,075-136,047-129,738-123,312-117,848-109,444-100,985-92,175-82,050-72,752-67,464-66,845-71,034-51,299-21,712-22,913-17,026-10,354-12,293-8,243-17,907-14,517
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
1,882
-24,641
-23,788
-1,467
0
16,470
68,471
70,244
110
3,337
-1,529
7,269
0
0
3,922
4,697
1,420
6,044
5,651
6,010
1,173
-10,500
-4,932
-4,627
0
0-4,627-4,932-10,5001,1736,0105,6516,0441,4204,6973,922007,269-1,5293,33711070,24468,47116,4700-1,467-23,788-24,6411,882



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue7,665
Cost of Revenue-3,760
Gross Profit3,9043,904
 
Operating Income (+$)
Gross Profit3,904
Operating Expense-16,115
Operating Income-12,210-12,210
 
Operating Expense (+$)
Research Development753
Selling General Administrative10,217
Selling And Marketing Expenses2,609
Operating Expense16,11513,579
 
Net Interest Income (+$)
Interest Income120
Interest Expense-52
Other Finance Cost-392
Net Interest Income-324
 
Pretax Income (+$)
Operating Income-12,210
Net Interest Income-324
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,017-12,403
EBIT - interestExpense = -12,017
-14,004
-11,966
Interest Expense52
Earnings Before Interest and Taxes (EBIT)-11,966-11,966
Earnings Before Interest and Taxes (EBITDA)-11,431
 
After tax Income (+$)
Income Before Tax-12,017
Tax Provision-0
Net Income From Continuing Ops-12,017-12,017
Net Income-12,017
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,210
Total Other Income/Expenses Net193324
 

Technical Analysis of Genetic Technologies Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genetic Technologies Ltd. The general trend of Genetic Technologies Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genetic Technologies Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Genetic Technologies Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genetic Technologies Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.039 < 0.039 < 0.039.

The bearish price targets are: 0.039 > 0.039 > 0.039.

Know someone who trades $GTG? Share this with them.👇

Genetic Technologies Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genetic Technologies Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genetic Technologies Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGenetic Technologies Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genetic Technologies Ltd. The current adx is .

Genetic Technologies Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Relative Strength Index (RSI) ChartGenetic Technologies Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Stochastic Oscillator ChartGenetic Technologies Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Commodity Channel Index (CCI) ChartGenetic Technologies Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Chande Momentum Oscillator (CMO) ChartGenetic Technologies Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Williams %R ChartGenetic Technologies Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Average True Range (ATR) ChartGenetic Technologies Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily On-Balance Volume (OBV) ChartGenetic Technologies Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genetic Technologies Ltd.

Genetic Technologies Ltd Daily Money Flow Index (MFI) ChartGenetic Technologies Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genetic Technologies Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Genetic Technologies Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genetic Technologies Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.039
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Genetic Technologies Ltd with someone you think should read this too:
  • Are you bullish or bearish on Genetic Technologies Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genetic Technologies Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genetic Technologies Ltd

I send you an email if I find something interesting about Genetic Technologies Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Genetic Technologies Ltd.

Receive notifications about Genetic Technologies Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.